Sagent introduces ceftazidime for injection, USP

Sagent will offer ceftazidime in one and 2g single dose vials and 6g pharmacy bulk package vials. Sagent’s introduction of ceftazidime to the US market is said to be the seventh product launched from Sagent’s pipeline of more than 200 products this year.

Sagent’s ceftazidime is the generic equivalent of GlaxoSmithKline’s Fortaz. It is used to treat bacterial infections, including infections of the lower respiratory tract; skin and skin-structure; urinary tract; bone and joint; and central nervous system.

Jeffrey Yordon, CEO of Sagent, said: “We are excited to make important products like ceftazidime available with exciting innovations, such as easy-to-read dosage strengths and precise lettering on vial labels that are intended to promote patient safety.”